Literature DB >> 12718671

HBV/HCV Infection, Alcohol, Tobacco and Genetic Polymorphisms for Hepatocellular Carcinoma in Nagoya, Japan.

Tsuneo Koide1, Tomoyoshi Ohno, Xin En Huang, Yoshiko Iijima, Kanji Sugihara, Masashi Mizokami, Jin Xiang, Shinkan Tokudome.   

Abstract

A population-based case-control study was carried out to investigate risk factors for hepatocellular carcinoma (HCC) in Nagoya, Japan, including hepatitis virus infections, drinking and smoking habits and genetic polymorphisms in aldehyde dehydrogenase2 (ALDH2) and cytochrome P4502E1 (CYP2E1). A total of 84 patients with HCC and 84 sex, age and residence pair-matched controls were recruited for this study. By univariate analysis, hepatitis B virus (HBV) (OR=5.14; 95%CI=2.29-11.6) and hepatitis C virus (HCV)(OR=32.00; 95%CI=7.83-130.7) infections, having a history of blood transfusion (OR=5.25; 95%CI=1.80-15.29), and habitual smoking (OR=2.36; 95%CI=1.17-4.78) were significantly linked to cases; by multivariate analysis, HCV infection (OR=23.5; 95%CI=5.07-108.9) and habitual smoking (OR=5.41; 95%CI=1.10-26.70) were still associated with a significantly increased risk. The c1/c1 genotype of CYP2E1 (odds ratio [OR]= 0.45; 95% confidence interval [CI]=0.21-0.99), detected by Pstl and Rsal digestion was significantly more prevalent in the control group, while 1-1 genotype of ALDH2 (OR=1.24; 95%CI=0.70-2.20) did not demonstrate variation. There were no statistically significant interactions between habitual smoking/drinking and genetic polymorphisms of ALDH2/P4502E1 with reference to HCC development. These findings suggest that viruses, especially HCV infection, and habitual smoking are major independent risk factors, while genetic polymorphisms of ALDH2 and CYP2E1 have only limited contribution to the risk of HCC in Nagoya, Japan.

Entities:  

Year:  2000        PMID: 12718671

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  7 in total

1.  Genetic polymorphisms of ALDH2 and ADH2 are not associated with risk of hepatocellular carcinoma among East Asians.

Authors:  Daming Zhou; Li Xiao; Yun Zhang; Jianchun Xian; Jijun Jiang; Wenhong Zong; Zuxuan Huang; Yongfeng Yang
Journal:  Tumour Biol       Date:  2012-01-10

Review 2.  Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures.

Authors:  Masahiro Tanaka; Francisco Katayama; Hideaki Kato; Hideo Tanaka; Jianbing Wang; You Lin Qiao; Manami Inoue
Journal:  J Epidemiol       Date:  2011-10-22       Impact factor: 3.211

3.  The effect of CYP, GST, and SULT polymorphisms and their interaction with smoking on the risk of hepatocellular carcinoma.

Authors:  Stefania Boccia; Luca Miele; Nikola Panic; Federica Turati; Dario Arzani; Consuelo Cefalo; Rosarita Amore; Milutin Bulajic; Maurizio Pompili; Gianlodovico Rapaccini; Antonio Gasbarrini; Carlo La Vecchia; Antonio Grieco
Journal:  Biomed Res Int       Date:  2015-01-14       Impact factor: 3.411

Review 4.  ALDH2 polymorphism and alcohol-related cancers in Asians: a public health perspective.

Authors:  Jeffrey S Chang; Jenn-Ren Hsiao; Che-Hong Chen
Journal:  J Biomed Sci       Date:  2017-03-03       Impact factor: 8.410

5.  Association of Heavy Alcohol Intake and ALDH2 rs671 Polymorphism With Hepatocellular Carcinoma and Mortality in Patients With Hepatitis B Virus-Related Cirrhosis.

Authors:  Ming-Chao Tsai; Sien-Sing Yang; Chih-Che Lin; Wen-Lun Wang; Yao-Chun Hsu; Yaw-Sen Chen; Jui-Ting Hu; James Yu Lin; Ming-Lung Yu; Chih-Wen Lin
Journal:  JAMA Netw Open       Date:  2022-07-01

6.  CYP2E1 PstI/RsaI polymorphism and interaction with alcohol consumption in hepatocellular carcinoma susceptibility: evidence from 1,661 cases and 2,317 controls.

Authors:  Chibo Liu; Haibao Wang; Chunqin Pan; Jianmin Shen; Yong Liang
Journal:  Tumour Biol       Date:  2012-01-17

7.  Genetic variants of ALDH2-rs671 and CYP2E1-rs2031920 contributed to risk of hepatocellular carcinoma susceptibility in a Chinese population.

Authors:  Xinping Ye; Xiangkun Wang; Liming Shang; Guangzhi Zhu; Hao Su; Chuangye Han; Wei Qin; Guanghui Li; Tao Peng
Journal:  Cancer Manag Res       Date:  2018-05-04       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.